CN111097066A - Medical dressing capable of inhibiting scar generation and promoting wound healing and preparation method thereof - Google Patents
Medical dressing capable of inhibiting scar generation and promoting wound healing and preparation method thereof Download PDFInfo
- Publication number
- CN111097066A CN111097066A CN202010027413.4A CN202010027413A CN111097066A CN 111097066 A CN111097066 A CN 111097066A CN 202010027413 A CN202010027413 A CN 202010027413A CN 111097066 A CN111097066 A CN 111097066A
- Authority
- CN
- China
- Prior art keywords
- medical dressing
- wound healing
- collagen
- human
- promoting wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0033—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
Abstract
The invention belongs to the field of medical dressings, and particularly relates to a medical dressing capable of inhibiting scar generation and promoting wound healing and a preparation method thereof. The medical dressing combines active ingredients such as human-like collagen, vascular endothelial growth factor, active polypeptide composition and the like, wherein the human-like collagen and the vascular endothelial growth factor can promote cell growth and regulate the repair process of wounds; the active polypeptide composition has the effects of promoting the repair of epidermal skin texture, wound recovery and tissue regeneration and reconstruction and effectively inhibiting the generation of scars. The components are matched for use, so that the tissue can be promoted to grow orderly, the wound healing process is accelerated, the synergistic effect is realized in the aspect of inhibiting the generation of scars, and the recurrence phenomenon is avoided after the treatment is finished.
Description
Technical Field
The invention belongs to the field of medical dressings, and particularly relates to a medical dressing capable of inhibiting scar generation and promoting wound healing and a preparation method thereof.
Background
The skin is a barrier between the human body and the external environment, and protects various tissues and organs in the body from external physical, mechanical, chemical and pathogenic microorganisms. When the skin is damaged, if the skin can not heal in time, the wound surface needs to be covered with the dressing in time. The medical dressing is used as a covering of a wound, can replace damaged skin to play a role of temporary barrier in the process of wound healing, avoids or controls wound infection, and provides an environment beneficial to wound healing. With the aging population and the increase of chronic ulcerative wounds, the market value of medical dressings is becoming more and more important. Depending on the materials used, medical dressings can be broadly divided into: natural materials, synthetic polymers, inorganic materials and composite materials. The main research directions of the current medical dressing are as follows: the defects of the existing material are improved and the performance of the material as a dressing is enhanced by a modification or composite method; various medicines and growth factors are loaded on the material, so that the medicine release is effectively controlled, and the wound healing and treating effects are achieved. From the perspective of patients, the number of dressing changes should be minimized to alleviate the pain caused by dressing changes.
The medical dressing should not only protect the wound surface, but also have the efficacy of promoting wound healing, and have corresponding special dressings for different wounds and different stages of wound healing, for example, scar tissue is not generated after wound healing. Scars are formed by human body wounds, scalds and postsurgical wounds due to lack of a regulation mechanism in the healing process of the wound surface and lack of protection of the healed skin. The current commonly used methods for scar repair are: surgical excision, external application of medicament, skin grafting, laser and the like, and also comprises means of polishing, filling and the like. From the viewpoint of the repairing effect, the recurrence rate of surgical excision and laser treatment is high, and some of the surgical excision and laser treatment can cause skin damage or local pain; traditional drug therapy can control the development of the disease and relieve symptoms, but the disease is not easy to cure. The research on the scar forming mechanism finds that: scars are mainly formed by excessive proliferation of fibrin and excessive deposition of collagen fibers, and are formed by local swelling, stiffness, discoloration due to imbalance in collagen synthesis and degradation, appearance of abnormal mucopolysaccharides, and proliferation of myofibroblasts. Therefore, in order to better meet the requirements of clinical treatment and use, the development of a new medical dressing capable of inhibiting scar generation and promoting wound healing is urgently needed in the market, and has important clinical significance in the aspect of treating skin wounds.
Disclosure of Invention
Aiming at the defects of the prior art, the technical problem to be solved by the invention is to provide a medical dressing for promoting wound healing and capable of inhibiting scar generation and a preparation method thereof. The medical dressing can effectively inhibit excessive proliferation and scar formation of fibrin by combining a plurality of active ingredients such as human-like collagen, vascular endothelial growth factor, active polypeptide composition and the like, and promote the ordered growth of tissues and the rapid healing of wounds.
In order to solve the technical problems, the invention adopts the technical scheme that:
a medical dressing for promoting wound healing and inhibiting scar generation comprises the following raw material components in percentage by weight: 1-3% of human-like collagen, 0.5-1% of vascular endothelial growth factor, 1-3% of active polypeptide composition, 2-6% of carboxymethyl chitosan, 10-16% of hydroxypropyl methyl cellulose and the balance of deionized water.
Preferably, the medical dressing for promoting wound healing comprises the following raw material components in percentage by weight: 1.2-2.5% of human-like collagen, 0.6-0.9% of vascular endothelial growth factor, 1.2-2.8% of active polypeptide composition, 3-5% of carboxymethyl chitosan, 11-15% of hydroxypropyl methyl cellulose and the balance of deionized water.
Preferably, the medical dressing for promoting wound healing comprises the following raw material components in percentage by weight: 1.5-2% of human-like collagen, 0.7-0.8% of vascular endothelial growth factor, 1.5-2.5% of active polypeptide composition, 3-4% of carboxymethyl chitosan, 12-14% of hydroxypropyl methyl cellulose and the balance of deionized water.
Preferably, the medical dressing for promoting wound healing comprises the following raw material components in percentage by weight: 1.5 percent of human-like collagen, 0.7 percent of vascular endothelial growth factor, 1.5 percent of active polypeptide composition, 3.5 percent of carboxymethyl chitosan, 13 percent of hydroxypropyl methyl cellulose and the balance of deionized water.
Preferably, the human-like collagen is a human-derived collagen produced by high-density fermentation of genetically recombinant escherichia coli.
Preferably, the active polypeptide composition is a composition with the weight ratio of acetyl tetrapeptide-2 to palmitoyl tripeptide-1 being 1: 1.
Further, the invention also provides application of the medical dressing in preparing a surgical wound material for inhibiting scar generation.
Further, the invention also provides a preparation method of the medical dressing for promoting wound healing, which comprises the following steps: adding carboxymethyl chitosan into a proper amount of deionized water, uniformly stirring in vacuum, and freeze-drying to obtain carboxymethyl chitosan hydrogel; putting human-like collagen, vascular endothelial growth factor, active polypeptide composition, hydroxypropyl methyl cellulose and the rest deionized water into a container according to the weight ratio, adding the prepared carboxymethyl chitosan hydrogel, uniformly stirring, and performing sterilization treatment to obtain the medical dressing.
Preferably, the sterilization treatment adopts Co-60 gamma ray irradiation for sterilization, and the sterilization dose is 60-80 kGy.
The human-like collagen is prepared by reverse transcription of a segment of mRNA of human body known sequence collagen to generate cDNA, repeating and modifying specific sequence, transforming into Escherichia coli, high-density fermentation, separation, extraction and purification. The collagen protein has the advantages of excellent property, low immunological rejection reaction, good biological absorbability, cell adhesion and biocompatibility, and capability of obviously promoting cell growth, thus being very suitable for being applied to the aspects of medicine, plastic and the like.
Vascular endothelial growth factor was first discovered in serum-free tumor cell culture and in animal cancerous ascites in 1979 by Dvorak et al, and was identified as a dimeric heparin affinity glycoprotein bound by disulfide bonds after analysis by Senger et al (1983) and was designated as Vascular Permeability Factor (VPF). Gospodalowicz and Ferrara et al (1989) isolated from bovine pituitary follicular cells an analog named as Vascular Endothelial Growth Factor (VEGF), which was analyzed to be the same cytokine with specificity for vascular endothelial cells. The vascular endothelial growth factor is an endogenous bioactive substance existing in a human body, can stimulate the proliferation of various cells, and has the effects of promoting the growth, proliferation and synthesis of the cells. VEGF can regulate the wound repair process and is an important factor influencing wound healing, so that the VEGF has good therapeutic effect on various diseases such as various wounds, burns, scalds and ulcers.
Acetyl tetrapeptide-2 is an active polypeptide containing 4 amino acids, and the amino acid sequence is as follows: Ac-D-Lys-Asp-Val-m-Tyr-NH2The modification of the 33-36 amino acid sequence of thymopoietin II has certain function of regulating the immune function of the organism and can enhance the immune defense of the skin; natural factors that maintain collagen levels and proper assembly of elastic fibers are enhanced, binding of cells to extracellular matrix is promoted, adverse effects that lead to loss of skin firmness and adhesion are resisted, and skin conditions are improved; it is mainly manifested by an increase in the thickness of the epidermis and a restoration of the epidermal skin texture. Acetyl tetrapeptide-2 has major applications: anti-aging, anti-wrinkle products, cosmeceutical products, post-operative care products, stretch mark removal products, nail and hair care products, and the like.
Palmitoyl tripeptide-1 is a matrikine signal peptide, which acts on the dermis layer, can promote the synthesis of extracellular matrix I and III type collagen, elastin, structural glycoproteins such as fibronectin and fibronectin, promote wound recovery and tissue renewal and reconstruction, strengthen the dermis layer, make the skin thicker and firmer, relieve wrinkles and resist the outside.
A large number of hydroxyl and amino active groups exist in the molecular structure of chitosan, and different chitosan derivatives can be obtained by various methods. The carboxymethyl chitosan is a water-soluble polysaccharide obtained by carboxymethylation of chitosan, has good antibacterial property, moisture retention property, hemostatic property and biocompatibility, is non-toxic and non-antigenic, and has better biodegradability than chitosan. In vitro experiments show that under physiological conditions, the carboxymethyl chitosan membrane can absorb water with the mass of 4 times, and meanwhile, the permeability of the carboxymethyl chitosan membrane is kept unchanged, so that the accumulation of wound secretions can be avoided.
Compared with the prior art, the invention has the beneficial effects that: the medical dressing combines active ingredients such as human-like collagen, vascular endothelial growth factor, active polypeptide composition and the like, wherein the human-like collagen and the vascular endothelial growth factor can promote cell growth and regulate the repair process of wounds; the active polypeptide composition has the effects of promoting the repair of epidermal skin texture, wound recovery and tissue regeneration and reconstruction and effectively inhibiting the generation of scars. The inventor unexpectedly finds that the components can promote the tissue to grow orderly and accelerate the wound healing process by matching and using, has synergistic effect on the aspect of inhibiting the generation of scars, and has no recurrence phenomenon after the treatment is finished. The thickening agent-hydroxypropyl methyl cellulose selected by the invention can stabilize the content of each protein active ingredient to be more than 95 percent within 6 months, and can keep stable and effective treatment effect for a long time. The medical dressing has the advantages of definite curative effect, safe and reliable use, no stimulation to skin, simple and quick preparation method and wide practical application value.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The materials, reagents and the like used are, unless otherwise specified, commercially available reagents and materials.
Example 1
A medical dressing for promoting wound healing and inhibiting scar generation comprises the following raw material components in percentage by weight: 2% of human-like collagen, 0.9% of vascular endothelial growth factor, 1.5% of active polypeptide composition (composition with the weight ratio of 1:1 of acetyl tetrapeptide-2 and palmitoyl tripeptide-1), 5% of carboxymethyl chitosan, 14% of hydroxypropyl methyl cellulose and the balance of deionized water.
Wherein, the human-like collagen is purchased from Novus Biologicals company in the United states; vascular endothelial growth factor was purchased from Sigma, usa; acetyl tetrapeptide-2 and palmitoyl tripeptide-1 are available from Zhejiang surge peptide biology, Inc.
The preparation method of the medical dressing for promoting wound healing comprises the following steps: adding carboxymethyl chitosan into a proper amount of deionized water, uniformly stirring in vacuum, and freeze-drying to obtain carboxymethyl chitosan hydrogel; putting human-like collagen, vascular endothelial growth factor, active polypeptide composition, hydroxypropyl methyl cellulose and the rest deionized water into a container according to the weight ratio, adding the prepared carboxymethyl chitosan hydrogel, uniformly stirring, and performing sterilization treatment to obtain the medical dressing.
Example 2
A medical dressing for promoting wound healing and inhibiting scar generation comprises the following raw material components in percentage by weight: 1% of human-like collagen, 0.6% of vascular endothelial growth factor, 2% of active polypeptide composition (composition with the weight ratio of 1:1 of acetyl tetrapeptide-2 and palmitoyl tripeptide-1), 4% of carboxymethyl chitosan, 12% of hydroxypropyl methyl cellulose and the balance of deionized water.
The preparation method of the medical dressing for promoting wound healing is the same as that of the example 1.
Example 3
A medical dressing for promoting wound healing and inhibiting scar generation comprises the following raw material components in percentage by weight: 1.5% of human-like collagen, 0.7% of vascular endothelial growth factor, 1.5% of active polypeptide composition (composition with the weight ratio of acetyl tetrapeptide-2 to palmitoyl tripeptide-1 being 1: 1), 3.5% of carboxymethyl chitosan, 13% of hydroxypropyl methyl cellulose and the balance of deionized water.
The preparation method of the medical dressing for promoting wound healing is the same as that of the example 1.
Comparative example 1 (No human-like collagen compared to example 3)
A medical dressing for promoting wound healing and inhibiting scar generation comprises the following raw material components in percentage by weight: 1% of vascular endothelial growth factor, 2.7% of active polypeptide composition (composition with the weight ratio of acetyl tetrapeptide-2 to palmitoyl tripeptide-1 being 1: 1), 3.5% of carboxymethyl chitosan, 13% of hydroxypropyl methyl cellulose and the balance of deionized water.
The preparation method of the medical dressing for promoting wound healing is the same as that of the example 1.
Comparative example 2 (in contrast to example 3, without vascular endothelial growth factor)
A medical dressing for promoting wound healing and inhibiting scar generation comprises the following raw material components in percentage by weight: 1.8% of human-like collagen, 1.9% of active polypeptide composition (composition with the weight ratio of acetyl tetrapeptide-2 to palmitoyl tripeptide-1 being 1: 1), 3.5% of carboxymethyl chitosan, 13% of hydroxypropyl methyl cellulose and the balance of deionized water.
The preparation method of the medical dressing for promoting wound healing is the same as that of the example 1.
Comparative example 3 (in contrast to example 3, without active polypeptide composition)
A medical dressing for promoting wound healing and inhibiting scar generation comprises the following raw material components in percentage by weight: 2.7% of human-like collagen, 1% of vascular endothelial growth factor, 3.5% of carboxymethyl chitosan, 13% of hydroxypropyl methyl cellulose and the balance of deionized water.
The preparation method of the medical dressing for promoting wound healing is the same as that of the example 1.
Storage stability test of medical dressing
The influence of different thickening agents (hydroxypropyl methylcellulose, alginic acid and xanthan gum) on the stability of active ingredients of human-like collagen, vascular endothelial growth factor, acetyl tetrapeptide-2, palmitoyl tripeptide-1 and other proteins is examined. Based on the composition of the medical dressing in example 1, hydroxypropyl methylcellulose was replaced with alginic acid and xanthan gum, the three medical dressings were placed in a constant temperature and humidity chamber (45 ℃ ± 2 ℃, humidity 75% ± 5%), the contents of acetyl tetrapeptide-2 and palmitoyl tripeptide-1 in each sample were measured by High Performance Liquid Chromatography (HPLC) at 3 rd and 6 th months, and the contents of human-like collagen and vascular endothelial growth factor were measured by an ELISA kit to evaluate the stability. The stability data are shown in table 1.
TABLE 1 determination of the active ingredient content of each protein by HPLC (indicated amount: 100%)
The test results in table 1 show that the thickening agent hydroxypropyl methylcellulose selected by the invention can stabilize the content of each protein active ingredient to be more than 95% within 6 months, and the stabilizing effect is obviously better than that of alginic acid and xanthan gum. This demonstrates that the medical dressing of the present invention has good storage stability and can maintain a stable and effective therapeutic effect over a long period of time.
Action of medical dressing on wound surface
Dividing healthy rats with weight of about 300g into 6 groups, each group containing 8 rats, injecting 3% sodium pentobarbital 30mg/kg into abdominal cavity for anesthesia, removing hair from two sides of spinal column of mouse, and the hair removal area is about 2cm2The depilated area is scalded by boiled water to form a wound surface containing more exudate, the scalded area is covered by the medical dressing for promoting wound healing prepared in the embodiments 1-3 and the comparative examples 1-3 of the invention, the dressing is changed once a day, and the wound healing and scar hyperplasia conditions are observed day by day. Evaluating the scar hyperplasia condition by adopting a grading system, and 5 grades till no scar is generated; 3 points, scars exist but are shallow, and the area of the scars is less than 50 percent of the area of the wound surface; 1 minute-scar with obvious scar, the area is more than 50% of the wound area. The test results are shown in table 2.
Table 2 therapeutic action of the inventive medical dressing for promoting wound healing on wound surface
The test results in table 2 show that the medical dressing for promoting wound healing can effectively inhibit excessive fibrin hyperplasia in the process of wound healing, prevent the protrusion and growth of scars, shorten the healing time of wounds, and prevent the wound surface from being inflamed after healing. Through contrast tests, the fact that the combination of three active ingredients, namely human-like collagen, vascular endothelial growth factor, active polypeptide composition and the like can promote the ordered growth of wound tissues and accelerate the healing process of wounds compared with the case that one active ingredient is lacked is unexpectedly found, and meanwhile, the synergistic effect on the aspect of inhibiting the generation of scars is achieved, and the recurrence phenomenon is avoided after the treatment is finished. The medical dressing has the advantages of definite curative effect, safe and reliable use, no stimulation to skin, simple and quick preparation method and wide practical application value.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications or equivalents may be made to the technical solution without departing from the principle of the present invention, and these modifications or equivalents should also be regarded as the protection scope of the present invention.
Claims (9)
1. The medical dressing capable of inhibiting scar generation and promoting wound healing is characterized by comprising the following raw material components in percentage by weight: 1-3% of human-like collagen, 0.5-1% of vascular endothelial growth factor, 1-3% of active polypeptide composition, 2-6% of carboxymethyl chitosan, 10-16% of hydroxypropyl methyl cellulose and the balance of deionized water.
2. The medical dressing for promoting wound healing according to claim 1, which is characterized by comprising the following raw material components in percentage by weight: 1.2-2.5% of human-like collagen, 0.6-0.9% of vascular endothelial growth factor, 1.2-2.8% of active polypeptide composition, 3-5% of carboxymethyl chitosan, 11-15% of hydroxypropyl methyl cellulose and the balance of deionized water.
3. The medical dressing for promoting wound healing according to claim 2, which is characterized by comprising the following raw material components in percentage by weight: 1.5-2% of human-like collagen, 0.7-0.8% of vascular endothelial growth factor, 1.5-2.5% of active polypeptide composition, 3-4% of carboxymethyl chitosan, 12-14% of hydroxypropyl methyl cellulose and the balance of deionized water.
4. The medical dressing for promoting wound healing according to claim 3, which is characterized by comprising the following raw material components in percentage by weight: 1.5 percent of human-like collagen, 0.7 percent of vascular endothelial growth factor, 1.5 percent of active polypeptide composition, 3.5 percent of carboxymethyl chitosan, 13 percent of hydroxypropyl methyl cellulose and the balance of deionized water.
5. The medical dressing for promoting wound healing according to any one of claims 1 to 4, wherein the human-like collagen is a human-derived collagen produced by high-density fermentation of genetically recombinant Escherichia coli.
6. A medical dressing for promoting wound healing according to any one of claims 1-4, wherein the active polypeptide composition is a composition of acetyl tetrapeptide-2 and palmitoyl tripeptide-1 in a weight ratio of 1: 1.
7. Use of a medical dressing according to any one of claims 1-6 for the manufacture of a surgical wound material for inhibiting scar formation.
8. The method for preparing a medical dressing for promoting wound healing according to any one of claims 1 to 6, comprising the steps of: adding carboxymethyl chitosan into a proper amount of deionized water, uniformly stirring in vacuum, and freeze-drying to obtain carboxymethyl chitosan hydrogel; putting human-like collagen, vascular endothelial growth factor, active polypeptide composition, hydroxypropyl methyl cellulose and the rest deionized water into a container according to the weight ratio, adding the prepared carboxymethyl chitosan hydrogel, uniformly stirring, and performing sterilization treatment to obtain the medical dressing.
9. The preparation method of the medical dressing for promoting wound healing according to claim 8, wherein the sterilization treatment adopts Co-60 gamma ray irradiation for sterilization, and the sterilization dose is 60-80 kGy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010027413.4A CN111097066A (en) | 2020-01-10 | 2020-01-10 | Medical dressing capable of inhibiting scar generation and promoting wound healing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010027413.4A CN111097066A (en) | 2020-01-10 | 2020-01-10 | Medical dressing capable of inhibiting scar generation and promoting wound healing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111097066A true CN111097066A (en) | 2020-05-05 |
Family
ID=70426084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010027413.4A Pending CN111097066A (en) | 2020-01-10 | 2020-01-10 | Medical dressing capable of inhibiting scar generation and promoting wound healing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111097066A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112245653A (en) * | 2020-11-13 | 2021-01-22 | 杭州伊瑟奇生物科技有限公司 | Protein film dressing assisting wound healing based on cooperation of three bioactive scaffold materials and cell trophic factors |
| CN112843220A (en) * | 2021-01-20 | 2021-05-28 | 温州医科大学附属第一医院 | Reverse protein stone membrane for inhibiting scar formation and preparation method thereof |
| CN114917184A (en) * | 2022-06-09 | 2022-08-19 | 溃克药业(哈尔滨)有限公司 | Viscous medical dressing and preparation process thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751768A (en) * | 2013-11-29 | 2014-04-30 | 焦阳 | Preparation helping to heal wound |
| CN103933603A (en) * | 2014-04-16 | 2014-07-23 | 广西信业生物技术有限公司 | Chitosan biological medical glue for promoting human epidermal growth and preparation method of biological medical glue |
| CN104288828A (en) * | 2014-10-29 | 2015-01-21 | 广西信业生物技术有限公司 | Medical biological scar-inhibiting rhytidectomy dressing and preparation method thereof |
| CN106729958A (en) * | 2016-12-12 | 2017-05-31 | 西北大学 | The method that internal bleeding-stopping dressing is prepared by programmed cooling |
| CN108743921A (en) * | 2018-05-24 | 2018-11-06 | 广州芬森医学科技有限公司 | It is a kind of to prevent the reparation liquid and its preparation method and application that scar is formed |
| WO2019094938A2 (en) * | 2017-11-13 | 2019-05-16 | The University Of Chicago | Methods and compositions for the treatment of wounds |
-
2020
- 2020-01-10 CN CN202010027413.4A patent/CN111097066A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751768A (en) * | 2013-11-29 | 2014-04-30 | 焦阳 | Preparation helping to heal wound |
| CN103933603A (en) * | 2014-04-16 | 2014-07-23 | 广西信业生物技术有限公司 | Chitosan biological medical glue for promoting human epidermal growth and preparation method of biological medical glue |
| CN104288828A (en) * | 2014-10-29 | 2015-01-21 | 广西信业生物技术有限公司 | Medical biological scar-inhibiting rhytidectomy dressing and preparation method thereof |
| CN106729958A (en) * | 2016-12-12 | 2017-05-31 | 西北大学 | The method that internal bleeding-stopping dressing is prepared by programmed cooling |
| WO2019094938A2 (en) * | 2017-11-13 | 2019-05-16 | The University Of Chicago | Methods and compositions for the treatment of wounds |
| CN108743921A (en) * | 2018-05-24 | 2018-11-06 | 广州芬森医学科技有限公司 | It is a kind of to prevent the reparation liquid and its preparation method and application that scar is formed |
Non-Patent Citations (1)
| Title |
|---|
| 汪多仁: "《现代高分子材料生产及应用手册》", 31 May 2002, 中国石化出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112245653A (en) * | 2020-11-13 | 2021-01-22 | 杭州伊瑟奇生物科技有限公司 | Protein film dressing assisting wound healing based on cooperation of three bioactive scaffold materials and cell trophic factors |
| CN112245653B (en) * | 2020-11-13 | 2022-07-01 | 杭州伊瑟奇生物科技有限公司 | Protein film dressing assisting wound healing based on cooperation of three bioactive scaffold materials and cell trophic factors |
| CN112843220A (en) * | 2021-01-20 | 2021-05-28 | 温州医科大学附属第一医院 | Reverse protein stone membrane for inhibiting scar formation and preparation method thereof |
| CN112843220B (en) * | 2021-01-20 | 2022-06-03 | 温州医科大学附属第一医院 | Reverse protein stone membrane for inhibiting scar formation and preparation method thereof |
| CN114917184A (en) * | 2022-06-09 | 2022-08-19 | 溃克药业(哈尔滨)有限公司 | Viscous medical dressing and preparation process thereof |
| CN114917184B (en) * | 2022-06-09 | 2023-01-10 | 溃克药业(哈尔滨)有限公司 | Viscous medical dressing and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111097066A (en) | Medical dressing capable of inhibiting scar generation and promoting wound healing and preparation method thereof | |
| US20040058858A1 (en) | Configuration of glycosaminoglycans | |
| EP0914168A1 (en) | New medicaments containing gelatin cross-linked with oxidized polysaccharides | |
| Arnold et al. | Wound healing: the effect of macrophage and tumour derived angiogenesis factors on skin graft vascularization. | |
| JPH05508148A (en) | Use of protease Nexin-I in mediating wound healing | |
| KR20130119674A (en) | A composition comprising alginate with fibroblast growth factor for wound healing | |
| Demling et al. | Small intestinal submucosa wound matrix and full-thickness venous ulcers: preliminary results | |
| WO2018144496A1 (en) | Methods and compositions for matrix preparation | |
| Zhou et al. | Efficacy of human adipose derived mesenchymal stem cells in promoting skin wound healing | |
| KR102473363B1 (en) | Spray type hydrogel wound coating preparation method and Spray type hydrogel wound coating thereof | |
| CN111097067A (en) | Antibacterial medical dressing for promoting wound to heal rapidly and preparation method thereof | |
| RU2706726C1 (en) | Wound coating | |
| Chen et al. | The role of gel wound dressings loaded with stem cells in the treatment of diabetic foot ulcers | |
| JP2017522392A5 (en) | ||
| CN113274410A (en) | Application of exosome hydrogel complex in preparation of medicine for repairing skin scar | |
| WO2013065017A2 (en) | Platelet rich plasma (prp) and prominin-1 derived peptide stimulate lymphangiogenesis | |
| AU2019383263B2 (en) | Pharmaceutical composition for treating cuts | |
| CN112107721A (en) | Synthetic dressing with biological effect and preparation method thereof | |
| Celani et al. | The effect of hyaluronic acid on the skin healing in rats | |
| Bai et al. | Metallic‐Polyphenolic Nanoparticles Reinforced Cationic Guar Gum Hydrogel for Effectively Treating Burn Wound | |
| Vojtová | Pavli náková | |
| Konop et al. | Keratin Biomaterials in Skin Wound Healing, an Old Player in Modern Medicine: A Mini Review. Pharmaceutics 2021, 13, 2029 | |
| US9662417B2 (en) | Medical device | |
| Gnatowski et al. | Polymers for burn dressings and skin substitutes | |
| JP2023050110A (en) | wound healing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |